Digipath Blog

Stay Up To Date With The Latest From Digipath

Digipath’s Dr. Cindy Orser Featured in Forbes Article on Cannabis Strains/Cultivars

Digipath’s Dr. Cindy Orser Featured in Forbes Article on Cannabis Strains/Cultivars

LAS VEGAS, NV, June 13, 2019 – Digipath, Inc. (OTCQB: DIGP) (“DIGP” or the “Company”), a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, is pleased to report that Chief Science Officer and Board member Dr. Cindy Orser was cited in an important new article in Forbes titled “Game Of Genomes: The Battle For The King Of Cannabis Strains Is Just Heating Up.”

The article, written by Forbes contributor Andre Bourque, addresses the messy nomenclature of the current cannabis market wherein an imprecise system of non-scientific names is used to identify and sell cannabis strains, or more accurately cannabis cultivars.

Mr. Bourque refers to Dr. Orser and her colleague Dr. Philippe Henry’s assertion that “the cannabis consumer patient often times has no real idea of the composition, consistency or comparability of the cannabis product that they purchase,” in their previous peer-reviewed publication “Making Sense of Cannabis Strains through Chemometrics,” in Cannabis Science & Technology.

“We are pleased to see this timely article draw attention to the issues faced by today’s cannabis consumers resulting from incorrect taxonomy and naming conventions. This is yet another example of Drs. Orser and Henry’s transformative work to illustrate and solve this problem,” stated Todd Denkin, CEO, Digipath. “With Dr. Orser on board as a true market leader in the science of cannabis, Digipath is committed to improving the way we cultivate, study, test and use cannabis.”

About Digipath, Inc. (OTCQB: DIGP)

Digipath, Inc., supports the cannabis industry’s best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry.  Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization.

Information about Forward-Looking Statements

This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Add comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.